Figure 3
Figure 3. CBMC-derived CXCL8 is crucial for CD56+ cell migration. Supernatants from poly(I:C) (p(I:C))– or medium (med)–stimulated CBMCs were incubated with anti-CXCL8 (0.4 μg/mL) or isotype control mAbs before being placed in the bottom chamber of 96-well chemotaxis assays. Poly(I:C) was added to medium alone to control for potential chemotactic/chemokinetic effects of the poly(I:C). Radiolabeled MACS-isolated CD56+ cells were placed in the top chamber, and chemotaxis was done for 2 hours. CXCL8 (30 ng/mL) was used as a positive control for mAb inhibition of chemotaxis. Mean migration to poly(I:C)-CBMC supernatants was 10.7%. Graphs represent the mean (± SEM) of the fold increase in chemotaxis over medium of 4 to 6 separate experiments. **P < .01 compared with CBMC medium; †P < .05, ††P < .01, compared with no treatment.

CBMC-derived CXCL8 is crucial for CD56+ cell migration. Supernatants from poly(I:C) (p(I:C))– or medium (med)–stimulated CBMCs were incubated with anti-CXCL8 (0.4 μg/mL) or isotype control mAbs before being placed in the bottom chamber of 96-well chemotaxis assays. Poly(I:C) was added to medium alone to control for potential chemotactic/chemokinetic effects of the poly(I:C). Radiolabeled MACS-isolated CD56+ cells were placed in the top chamber, and chemotaxis was done for 2 hours. CXCL8 (30 ng/mL) was used as a positive control for mAb inhibition of chemotaxis. Mean migration to poly(I:C)-CBMC supernatants was 10.7%. Graphs represent the mean (± SEM) of the fold increase in chemotaxis over medium of 4 to 6 separate experiments. **P < .01 compared with CBMC medium; †P < .05, ††P < .01, compared with no treatment.

Close Modal

or Create an Account

Close Modal
Close Modal